This superior performance highlights the potential of our approach in accelerating the discovery and optimization of novel, potent ADC payloads, particularly those targeting DNA Topoisomerase I, potentially leading to more effective and targeted cancer therapies. This evidence concerns the gene TOP1 and cancer.